Other languages YS Biopharma Co., Ltd.

Equities

YS

KYG9845F1090

Delayed Nasdaq Other stock markets 08:23:50 24/05/2024 pm IST			5-day change	1st Jan Change
0.9461 ^USD	+4.30%		-3.25%	+85.15%

04:36pm	YS Biopharma to Become LakeShore Biopharma, Ticker Symbol to Change to LSB From YS Starting May 28	MT
21/05	YS Biopharma Co., Ltd. Approves Board Appointments	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

YS Biopharma Co., Ltd. Approves Board Appointments	22/05
YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023	19/04
YS Biopharma Co., Ltd. Grants Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine	18/04
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of Pika Rabies Vaccine	09/04
YS Biopharma Co., Ltd. Announces Board Changes	05/03
YS Biopharma Co., Ltd. Announces Board Changes	23/02
YS Biopharma Co., Ltd. Announces Board Resignations	17/02
YS Biopharma Co., Ltd. Announces Chief Executive Officer Changes	17/02
YS Biopharma Co., Ltd. Announces Management Changes	17/02
YS Biopharma Receives a Notice from APEX Prospect Limited	14/02
YS Biopharma Co., Ltd. Announces Appointment of New Directors	14/02
Ys Biopharma Co., Ltd. Announces Board Resignations	09/02
YS Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2023	23/01
YS Biopharma Co., Ltd. Appoints Rui Yu as Chairperson of Its Audit Committee, as Member of Its Compensation Committee, and as Member of the Nominating and Corporate Governance Committee	08/01
YS Biopharma Co., Ltd. Announces Board Changes	12/12
YS Biopharma Co., Ltd. Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine	31/23/31
YS Biopharma Enrolls 1st Subject in Late-Stage Rabies Vaccine Clinical Trial; Shares Rise	26/23/26
YS Biopharma Co., Ltd. Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine	26/23/26
YS Biopharma Says it Obtained US Patent for Immunotherapy Targeting Chronic Hepatitis B; Shares Gain Pre-Bell	15/23/15
Ys Biopharma Co., Ltd. Grants Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection	15/23/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages YS Biopharma Co., Ltd.

Equities

YS

KYG9845F1090

Other languages

Filters